Meeting
2018 ASCO Annual Meeting
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
Authors
Lore Decoster
UZ Brussel, Brussels, Belgium
Lore Decoster , Nadia Cappoen , Philippe Georges Aftimos , Gordana Raicevic , Christian Diego Rolfo , Sylvie Rottey , Francois P. Duhoux , Joelle Collignon , Aline Hebrant , Marc Vandenbulcke , Jacques De Greve
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
2016-003411-34
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2615)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2615
Abstract #
TPS2615
Poster Bd #
431b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2012 ASCO Annual Meeting
First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.
First Author: Mark G. Kris
Poster
2021 ASCO Annual Meeting
Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.
First Author: Jianwen Qin